Showing 7241-7250 of 10729 results for "".
Patient Education: The Heart of Your Plan
https://practicaldermatology.com/topics/practice-management/patient-education-the-heart-of-your-plan/20928/Your office must be equipped with proper strategies to engage and educate if you want to make a lasting impression with your patients.PBM Restrictions Force Dermatologists to Consider OTC Products
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pbm-restrictions-force-dermatologists-to-consider-otc-products/23578/The latest generation of OTC products for some common dermatologic diseases often feature innovative formulations and clinical studies to show efficacy.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuGreat Expectations
https://practicaldermatology.com/topics/practice-management/great-expectations/20607/A look ahead to hot topics at Cosmetic Surgery Forum 2017Raising Issues with MOC
https://practicaldermatology.com/topics/practice-management/raising-issues-with-moc/21195/Dermatologists and the AAD speak out against current MOC requirements and suggest changes.Atopic Dermatitis: A Review of Common Comorbidities
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-a-review-of-common-comorbidities/23352/It is important to acknowledge and identify comorbidities to successfully manage AD and improve patient quality of life.Dealing with the Crazy Cost Curve in Dermatologic Drugs
https://practicaldermatology.com/topics/practice-management/dealing-with-the-crazy-cost-curve-in-dermatologic-drugs/20376/Dermatologists, desperate for relief from the forces that have sent prices skyrocketing, are pushing for reform or exploring other options.A Definitive Guide to Recognizing and Treating “Maskne”
https://practicaldermatology.com/columns/clinical-focus-1/a-definitive-guide-to-recognizing-and-treating-maskne/23520/Practical Dermatology® magazine’s resident acne columnist offers step-by-step guidance.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyOpen Payments Program: Does it Enhance Open Discussion About Financial Ties Between Dermatologists and Industry?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/open-payments-program-does-it-enhance-open-discussion-about-financial-ties-between-dermatologists-and-industry/23619/The majority of physicians practicing in the United States have received some form of compensation from private industry during their careers. These payments may include consulting fees, compensation for speaking engagements, and stock options. Certain payments take indirect forms, such as physic